• Vaccine Name: LYB001
• Target Pathogen: SARS-CoV-2
• Target Disease: COVID-19
• Manufacturer: Yantai Patronus Biotech Co., Ltd.
• Vaccine Ontology ID: VO_0005348
• Type: Virus Like Particle
• Status: Clinical trial
• Host Species for Licensed Use: Human
• Immunization Route: Intramuscular injection (i.m.)
• Description: Phase I: NCT05125926 (NCT05125926)

Human Response

• Vaccination Protocol: The study vaccine will be administered IM at upper arm deltoid as a three-dose regimen with 28d interval on day 0, 28, 56.
• Description: This is a randomized, double-blind, placebo-controlled Phase Ⅰ trial in healthy adults aged 18 years and older, intended to evaluate the safety, reactogenicity, and immunogenicity profile of LYB001 (NCT05125926)